Lahore: BF Biosciences Limited, in its annual general meeting held on October 28, 2026, ratified several key resolutions, focusing on its financial and operational strategies for the upcoming year. The meeting underscored the company's commitment to maintaining financial transparency and accountability.

The shareholders confirmed the minutes of the previous annual general meeting held on October 25, 2025. The resolution authorized the Chief Executive Officer to sign these minutes on behalf of the shareholders, thereby formalizing the documentation process.

In a significant move, the company's audited financial statements for the year ending June 30, 2026, were approved and adopted. This included the Chairman's Review, Directors', and Auditors' Reports, reflecting the company's financial health and governance practices over the past fiscal year.

The appointment of Messrs. KPMG Taseer Hadi & Co., Chartered Accountants, was reaffirmed as the external auditors for the year ending June 30, 2027. Their remuneration, recommended by the Board of Directors, was also approved, ensuring continuity in the company’s auditing processes.

A special resolution was passed to ratify related party transactions conducted during the financial year 2025-26. According to information available from the Pakistan Stock Exchange (PSX), these transactions, detailed in Note 36 of the financial statements, were confirmed, and the Board of Directors was empowered to approve future related party transactions as deemed appropriate.

These resolutions highlight BF Biosciences Limited's focus on adhering to regulatory standards and enhancing corporate governance, key factors in maintaining market confidence and operational integrity.